MEF2C regulates cortical inhibitory and excitatory synapses and behaviors relevant to neurodevelopmental disorders

  1. Adam J Harrington
  2. Aram Raissi
  3. Kacey Rajkovich
  4. Stefano Berto
  5. Jaswinder Kumar
  6. Gemma Molinaro
  7. Jonathan Raduazzo
  8. Yuhong Guo
  9. Kris Loerwald
  10. Genevieve Konopka
  11. Kimberly M Huber
  12. Christopher W Cowan  Is a corresponding author
  1. Medical University of South Carolina, United States
  2. Harvard Medical School, United States
  3. The University of Texas Southwestern Medical Center, United States

Abstract

Numerous genetic variants associated with MEF2C are linked to autism, intellectual disability (ID) and schizophrenia (SCZ) - a heterogeneous collection of neurodevelopmental disorders with unclear pathophysiology. MEF2C is highly expressed in developing cortical excitatory neurons, but its role in their development remains unclear. We show here that conditional embryonic deletion of Mef2c in cortical and hippocampal excitatory neurons (Emx1-lineage) produces a dramatic reduction in cortical network activity in vivo, due in part to a dramatic increase in inhibitory and a decrease in excitatory synaptic transmission. In addition, we find that MEF2C regulates E/I synapse density predominantly as a cell-autonomous, transcriptional repressor. Analysis of differential gene expression in Mef2c mutant cortex identified a significant overlap with numerous synapse- and autism-linked genes, and the Mef2c mutant mice displayed numerous behaviors reminiscent of autism, ID and SCZ, suggesting that perturbing MEF2C function in neocortex can produce autistic- and ID-like behaviors in mice.

Data availability

The following data sets were generated

Article and author information

Author details

  1. Adam J Harrington

    Department of Neuroscience, Medical University of South Carolina, Charleston, United States
    Competing interests
    The authors declare that no competing interests exist.
  2. Aram Raissi

    Department of Psychiatry, Harvard Medical School, Belmont, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Kacey Rajkovich

    Department of Neuroscience, The University of Texas Southwestern Medical Center, Dallas, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Stefano Berto

    Department of Neuroscience, The University of Texas Southwestern Medical Center, Dallas, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Jaswinder Kumar

    Department of Psychiatry, Harvard Medical School, Belmont, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Gemma Molinaro

    Department of Neuroscience, The University of Texas Southwestern Medical Center, Dallas, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Jonathan Raduazzo

    Department of Psychiatry, Harvard Medical School, Belmont, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Yuhong Guo

    Department of Psychiatry, Harvard Medical School, Belmont, United States
    Competing interests
    The authors declare that no competing interests exist.
  9. Kris Loerwald

    Department of Neuroscience, The University of Texas Southwestern Medical Center, Dallas, United States
    Competing interests
    The authors declare that no competing interests exist.
  10. Genevieve Konopka

    Department of Neuroscience, The University of Texas Southwestern Medical Center, Dallas, United States
    Competing interests
    The authors declare that no competing interests exist.
  11. Kimberly M Huber

    Department of Neuroscience, The University of Texas Southwestern Medical Center, Dallas, United States
    Competing interests
    The authors declare that no competing interests exist.
  12. Christopher W Cowan

    Department of Neuroscience, Medical University of South Carolina, Charleston, United States
    For correspondence
    cowanc@musc.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5472-3296

Funding

Eunice Kennedy Shriver National Institute of Child Health and Human Development

  • Adam J Harrington

Simons Foundation (SFARI #206919)

  • Kimberly M Huber
  • Christopher W Cowan

National Institute on Drug Abuse

  • Christopher W Cowan

NIH Office of the Director

  • Kimberly M Huber

National Institutes of Health (F32 HD078050)

  • Adam J Harrington

National Institutes of Health (DA027664)

  • Christopher W Cowan

National Institutes of Health (HD052731)

  • Kimberly M Huber

National Institutes of Health (OD010737)

  • Christopher W Cowan

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the NIH. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols (#2015N000178 and #2015N000160) of McLean Hospital.

Copyright

© 2016, Harrington et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 6,400
    views
  • 1,176
    downloads
  • 157
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Adam J Harrington
  2. Aram Raissi
  3. Kacey Rajkovich
  4. Stefano Berto
  5. Jaswinder Kumar
  6. Gemma Molinaro
  7. Jonathan Raduazzo
  8. Yuhong Guo
  9. Kris Loerwald
  10. Genevieve Konopka
  11. Kimberly M Huber
  12. Christopher W Cowan
(2016)
MEF2C regulates cortical inhibitory and excitatory synapses and behaviors relevant to neurodevelopmental disorders
eLife 5:e20059.
https://doi.org/10.7554/eLife.20059

Share this article

https://doi.org/10.7554/eLife.20059

Further reading

    1. Neuroscience
    François Kroll, Joshua Donnelly ... Jason Rihel
    Research Article

    By exposing genes associated with disease, genomic studies provide hundreds of starting points that should lead to druggable processes. However, our ability to systematically translate these genomic findings into biological pathways remains limited. Here, we combine rapid loss-of-function mutagenesis of Alzheimer’s risk genes and behavioural pharmacology in zebrafish to predict disrupted processes and candidate therapeutics. FramebyFrame, our expanded package for the analysis of larval behaviours, revealed that decreased night-time sleep was common to F0 knockouts of all four late-onset Alzheimer’s risk genes tested. We developed an online tool, ZOLTAR, which compares any behavioural fingerprint to a library of fingerprints from larvae treated with 3677 compounds. ZOLTAR successfully predicted that sorl1 mutants have disrupted serotonin signalling and identified betamethasone as a drug which normalises the excessive day-time sleep of presenilin-2 knockout larvae with minimal side effects. Predictive behavioural pharmacology offers a general framework to rapidly link disease-associated genes to druggable pathways.

    1. Neuroscience
    Kaspar E Vogt, Ashwinikumar Kulkarni ... Robert W Greene
    Research Article

    Sleep loss increases AMPA-synaptic strength and number in the neocortex. However, this is only part of the synaptic sleep loss response. We report an increased AMPA/NMDA EPSC ratio in frontal-cortical pyramidal neurons of layers 2–3. Silent synapses are absent, decreasing the plastic potential to convert silent NMDA to active AMPA synapses. These sleep loss changes are recovered by sleep. Sleep genes are enriched for synaptic shaping cellular components controlling glutamate synapse phenotype, overlap with autism risk genes, and are primarily observed in excitatory pyramidal neurons projecting intra-telencephalically. These genes are enriched with genes controlled by the transcription factor, MEF2c, and its repressor, HDAC4. Sleep genes can thus provide a framework within which motor learning and training occur mediated by the sleep-dependent oscillation of glutamate-synaptic phenotypes.